CA2368309A1 - Peptide variants of the tumour marker muc1 and the use thereof - Google Patents
Peptide variants of the tumour marker muc1 and the use thereof Download PDFInfo
- Publication number
- CA2368309A1 CA2368309A1 CA002368309A CA2368309A CA2368309A1 CA 2368309 A1 CA2368309 A1 CA 2368309A1 CA 002368309 A CA002368309 A CA 002368309A CA 2368309 A CA2368309 A CA 2368309A CA 2368309 A1 CA2368309 A1 CA 2368309A1
- Authority
- CA
- Canada
- Prior art keywords
- pap20
- sequence
- seq
- muc1
- peptide variants
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 36
- 239000000439 tumor marker Substances 0.000 title abstract description 4
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 title 1
- 102100034256 Mucin-1 Human genes 0.000 claims abstract description 23
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims abstract description 22
- 230000002163 immunogen Effects 0.000 claims abstract description 4
- 230000000890 antigenic effect Effects 0.000 claims abstract description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 229960005486 vaccine Drugs 0.000 claims description 5
- 230000009946 DNA mutation Effects 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 230000003327 cancerostatic effect Effects 0.000 claims 1
- 230000003252 repetitive effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 6
- 108010063954 Mucins Proteins 0.000 description 4
- 102000015728 Mucins Human genes 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 108090001092 clostripain Proteins 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19906615.9 | 1999-02-17 | ||
| DE19906615A DE19906615A1 (de) | 1999-02-17 | 1999-02-17 | Peptid-Varianten des Tumormarkers MUC1 und ihre Verwendung |
| PCT/DE2000/000440 WO2000049045A1 (de) | 1999-02-17 | 2000-02-17 | Peptid-varianten des tumormarkers muc1 und ihre verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2368309A1 true CA2368309A1 (en) | 2000-08-24 |
Family
ID=7897778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002368309A Abandoned CA2368309A1 (en) | 1999-02-17 | 2000-02-17 | Peptide variants of the tumour marker muc1 and the use thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20090054622A1 (enExample) |
| EP (1) | EP1151005B1 (enExample) |
| JP (1) | JP2002541067A (enExample) |
| AT (1) | ATE243222T1 (enExample) |
| AU (1) | AU772709B2 (enExample) |
| CA (1) | CA2368309A1 (enExample) |
| DE (2) | DE19906615A1 (enExample) |
| DK (1) | DK1151005T3 (enExample) |
| ES (1) | ES2200851T3 (enExample) |
| WO (1) | WO2000049045A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003266236A1 (en) | 2002-07-22 | 2004-02-09 | Nemod Immuntherapie Ag | Method for the production of an immunostimulating mucin (muc1) |
| US9346867B2 (en) | 2010-04-19 | 2016-05-24 | Sumitomo Bakelite Co., Ltd. | Cancer-related glycopeptide epitopes, antibodies and methods of use |
| KR102049928B1 (ko) | 2011-08-17 | 2019-11-28 | 글로브이뮨 | 효모-muc1 면역요법 조성물 및 그 용도 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3023469B2 (ja) * | 1992-02-21 | 2000-03-21 | 株式会社日本抗体研究所 | 糖タンパク質３９遺伝子 |
| US6120765A (en) * | 1993-04-02 | 2000-09-19 | Shiseido Co. Ltd. | Urokinase plasminogen activator fragments |
| US5744144A (en) * | 1993-07-30 | 1998-04-28 | University Of Pittsburgh University Patent Committee Policy And Procedures | Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof |
| AU727308B2 (en) * | 1997-02-24 | 2000-12-07 | Dana-Farber Cancer Institute | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
-
1999
- 1999-02-17 DE DE19906615A patent/DE19906615A1/de not_active Withdrawn
-
2000
- 2000-02-17 CA CA002368309A patent/CA2368309A1/en not_active Abandoned
- 2000-02-17 WO PCT/DE2000/000440 patent/WO2000049045A1/de not_active Ceased
- 2000-02-17 DK DK00916753T patent/DK1151005T3/da active
- 2000-02-17 DE DE50002584T patent/DE50002584D1/de not_active Expired - Fee Related
- 2000-02-17 AT AT00916753T patent/ATE243222T1/de not_active IP Right Cessation
- 2000-02-17 AU AU38013/00A patent/AU772709B2/en not_active Ceased
- 2000-02-17 JP JP2000599782A patent/JP2002541067A/ja active Pending
- 2000-02-17 EP EP00916753A patent/EP1151005B1/de not_active Expired - Lifetime
- 2000-02-17 ES ES00916753T patent/ES2200851T3/es not_active Expired - Lifetime
-
2001
- 2001-08-16 US US09/931,638 patent/US20090054622A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK1151005T3 (da) | 2003-10-13 |
| ATE243222T1 (de) | 2003-07-15 |
| DE50002584D1 (de) | 2003-07-24 |
| AU772709B2 (en) | 2004-05-06 |
| EP1151005A1 (de) | 2001-11-07 |
| ES2200851T3 (es) | 2004-03-16 |
| JP2002541067A (ja) | 2002-12-03 |
| AU3801300A (en) | 2000-09-04 |
| US20090054622A1 (en) | 2009-02-26 |
| DE19906615A1 (de) | 2000-09-28 |
| EP1151005B1 (de) | 2003-06-18 |
| WO2000049045A1 (de) | 2000-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Morris et al. | Isolation and characterization of human calcitonin gene-related peptide | |
| Rydlander et al. | Molecular characterization of a tissue‐polypeptide‐specific‐antigen epitope and its relationship to human cytokeratin 18 | |
| AU2007202776B2 (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
| CA2188432A1 (en) | Melanoma antigens | |
| EA013876B1 (ru) | Опухолеассоциированные пептиды, беспорядочно связывающиеся с молекулами класса ii человеческого лейкоцитарного антигена (hla) | |
| CA2289912A1 (en) | Human receptor proteins; related reagents and methods | |
| EP2118128B1 (en) | Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1 | |
| US7247712B2 (en) | Complex of hepatitis B virus-specific antigenic peptides associated with heat shock proteins and the application thereof | |
| CA2763486A1 (en) | Casb7439 constructs | |
| AU2759895A (en) | Recombinant allergen, fragments thereof, corresponding recombinant dna molecules, vectors and hosts containing the dna molecules, diagnostic and therapeutic uses of said allergens and fragments | |
| CA2660064C (en) | Promiscuous pap cd4 t cell epitopes | |
| WO2007079783A1 (en) | Enzymatic large-scale synthesis of mucin glyconjugates, and immunogenic applications thereof | |
| US8309096B2 (en) | Fusion protein | |
| AU772709B2 (en) | Peptide variants of the tumour marker MUC1 and the use thereof | |
| Cremer et al. | Synthesis of branched oxime‐linked peptide mimetics of the MUC1 containing a universal T‐helper epitope | |
| JP2001515720A (ja) | β−デフェンシン | |
| CN101015689A (zh) | 基于血管紧张素ⅱ的肿瘤多肽疫苗 | |
| CN100402551C (zh) | β2-微球蛋白的抗原表位及应用 | |
| EP1103561B1 (en) | Hla-a2 restraint tumor antigen peptide originating in sart-1 | |
| WO2023020615A1 (en) | Efficient expression system of sars-cov-2 receptor binding domain (rbd), methods for purification and use thereof | |
| CN101885758A (zh) | 一种自身抗原表位、其编码基因及其用途 | |
| AU2014274586B2 (en) | Nucleic acids and proteins from streptococcus groups A & B | |
| TWI670280B (zh) | 人類乳突病毒之脂質抗原及用於人類乳突病毒相關疾病之免疫治療組合物 | |
| WO2003023006A2 (en) | Hemocyanin nucleic acids and polypeptides and related vectors, fusion proteins, conjugates, cells and methods of use | |
| CN113318225A (zh) | 肿瘤免疫增强剂及其制法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |